Mehmet Bilen, MD

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics, Pfizer
    Date added:
    11/13/2024
    Date updated:
    11/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi
    Topic:
    ad board
    Date added:
    11/13/2024
    Date updated:
    11/13/2024
Return to Atlanta Genitourinary Cancers Summit